Loading...

← Back to Leaderboard

Mark Sculpher

Global rank #8305 90%

Institution: Unknown

Primary Field: Health (weighted toward more recent publications)

Homepage: https://www.york.ac.uk/che/staff/research/mark-sculpher/

First Publication: 1995

Most Recent: 2024

RePEc ID: psc810 ↗

Publication Scores

Scores use coauthorship adjustment: α/n credit per paper, where n = number of authors. α = 2.01: calibrated so average adjusted count equals average raw count (a zero-sum adjustment).

Period S (4x) A (2x) B (1x) C (½x) Total
Last 5 Years 0.00 0.00 0.90 0.00 0.90
Last 10 Years 0.00 0.00 2.92 0.00 2.92
All Time 0.00 0.00 12.47 0.00 12.47

Publication Statistics

Raw Publications 20
Coauthorship-Adjusted Count 12.52

Publications (20)

Year Article Journal Tier Authors
2024 Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required Health Economics B 5
2021 Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems Health Economics B 4
2020 Distributional cost effectiveness analysis of West Yorkshire low emission zone policies Health Economics B 3
2018 Social value and individual choice: The value of a choice‐based decision‐making process in a collectively funded health system Health Economics B 4
2018 How to design the cost‐effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework Health Economics B 4
2017 Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs Health Economics B 6
2015 CAUSES FOR CONCERN: IS NICE FAILING TO UPHOLD ITS RESPONSIBILITIES TO ALL NHS PATIENTS? Health Economics B 4
2011 Dangerous omissions: the consequences of ignoring decision uncertainty Health Economics B 4
2010 Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods Health Economics B 2
2006 Discounting and cost‐effectiveness in NICE – stepping back to sort out a confusion Health Economics B 8
2006 Whither trial‐based economic evaluation for health care decision making? Health Economics B 4
2006 Evidence synthesis, parameter correlation and probabilistic sensitivity analysis Health Economics B 3
2005 Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra Health Economics B 8
2005 Assessing generalisability by location in trial‐based cost‐effectiveness analysis: the use of multilevel models Health Economics B 4
2005 Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utility Health Economics B 3
2002 Recognising diversity in public preferences: the use of preference sub‐groups in cost‐effectiveness analysis. Authors' reply Health Economics B 2
2001 Representing uncertainty: the role of cost‐effectiveness acceptability curves Health Economics B 3
2001 Recognizing diversity in public preferences: The use of preference sub‐groups in cost‐effectiveness analysis Health Economics B 2
1998 The cost‐effectiveness of preference‐based treatment allocation: the case of hysterectomy versus endometrial resection in the treatment of menorrhagia Health Economics B 1
1995 Sensitivity analysis in economic evaluation: A review of published studies Health Economics B 2